Valuation implications of pharmaceutical companies' R&D regulatory approval notifications
Year of publication: |
2013
|
---|---|
Authors: | Hamill, Philip ; McIlkenny, Philip ; Opong, Kwaku K. |
Published in: |
The British accounting review : the journal of the British Accounting Association. - Amsterdam [u.a.] : Elsevier, ISSN 0890-8389, ZDB-ID 1015419-X. - Vol. 45.2013, 2, p. 99-111
|
Subject: | Pharmaindustrie | Pharmaceutical industry | Regulierung | Regulation | Arzneimittel | Pharmaceuticals |
-
Therapeutic substitution post-patent expiry : the cases of ACE inhibitors and proton pump inhibitors
Vandoros, Sotris, (2014)
-
Demortain, David, (2015)
-
Umbrella branding in pharmaceutical markets
Suppliet, Moritz, (2017)
- More ...
-
Directors' Share Dealings and Company Financial Performance
Hamill, Philip, (2002)
-
Board effectiveness and firm performance of Canadian listed firms
Conheady, Brian, (2015)
-
Valuation implications of pharmaceutical companies' R&D regulatory approval notifications
Hamill, Philip A., (2013)
- More ...